JP2021514664A5 - - Google Patents

Info

Publication number
JP2021514664A5
JP2021514664A5 JP2020546942A JP2020546942A JP2021514664A5 JP 2021514664 A5 JP2021514664 A5 JP 2021514664A5 JP 2020546942 A JP2020546942 A JP 2020546942A JP 2020546942 A JP2020546942 A JP 2020546942A JP 2021514664 A5 JP2021514664 A5 JP 2021514664A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514664A (ja
JP7398380B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020872 external-priority patent/WO2019173420A1/en
Publication of JP2021514664A publication Critical patent/JP2021514664A/ja
Publication of JP2021514664A5 publication Critical patent/JP2021514664A5/ja
Application granted granted Critical
Publication of JP7398380B2 publication Critical patent/JP7398380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546942A 2018-03-08 2019-03-06 抗クローディン１８．２抗体及びその使用 Active JP7398380B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862640288P 2018-03-08 2018-03-08
US62/640,288 2018-03-08
US201862714254P 2018-08-03 2018-08-03
US62/714,254 2018-08-03
PCT/US2019/020872 WO2019173420A1 (en) 2018-03-08 2019-03-06 Anti-claudin 18.2 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2021514664A JP2021514664A (ja) 2021-06-17
JP2021514664A5 true JP2021514664A5 (https=) 2022-03-10
JP7398380B2 JP7398380B2 (ja) 2023-12-14

Family

ID=67847436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020546942A Active JP7398380B2 (ja) 2018-03-08 2019-03-06 抗クローディン１８．２抗体及びその使用

Country Status (13)

Country Link
US (1) US11555070B2 (https=)
EP (1) EP3762031A4 (https=)
JP (1) JP7398380B2 (https=)
KR (1) KR102784161B1 (https=)
CN (1) CN111836644B (https=)
AU (1) AU2019232762B2 (https=)
BR (1) BR112020015479A2 (https=)
CA (1) CA3089653A1 (https=)
IL (1) IL276830B2 (https=)
MX (1) MX2020009326A (https=)
SG (1) SG11202007055QA (https=)
WO (1) WO2019173420A1 (https=)
ZA (1) ZA202004730B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210110339A (ko) * 2018-12-28 2021-09-07 난징 진스크립트 바이오테크 컴퍼니 리미티드 클라우딘18.2 결합 모이어티 및 그 용도
SG11202108398YA (en) 2019-02-01 2021-08-30 Novarock Biotherapeutics Ltd Anti-claudin 18 antibodies and methods of use thereof
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
KR102777693B1 (ko) * 2019-07-17 2025-03-07 더 리전트 오브 더 유니버시티 오브 캘리포니아 Claudin18 항체 및 암 치료 방법
JP7767270B2 (ja) * 2019-08-20 2025-11-11 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｃｌｄｎ１８．２抗体
WO2021047599A1 (en) * 2019-09-13 2021-03-18 Beijing Xuanyi Pharmasciences Co., Ltd. Humanized anti-claudin 18.2 (cldn18.2) antibodies
CN112574307B (zh) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
US20230030674A1 (en) 2019-12-06 2023-02-02 Sotio Biotech A.S. Humanized cldn18.2 antibodies
WO2021130291A1 (en) 2019-12-23 2021-07-01 SOTIO a.s. Tumor-specific claudin 18.2 antibodies
AU2021204861B2 (en) * 2020-01-03 2024-10-17 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
CN114981308A (zh) * 2020-01-19 2022-08-30 南京金斯瑞生物科技有限公司 多特异性抗密蛋白-18.2构建体及其用途
AU2021220887B2 (en) * 2020-02-10 2024-11-21 Shanghai Escugen Biotechnology Co., Ltd. CLDN18.2 antibody and use thereof
JP7522482B2 (ja) * 2020-02-10 2024-07-25 上海詩健生物科技有限公司 クローディン１８．２の抗体及びその使用
WO2021163989A1 (en) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
WO2021238831A1 (en) * 2020-05-25 2021-12-02 Mabspace Biosciences (Suzhou) Co., Limited Anti-cldn18.2 antibodies and diagnostic uses thereof
WO2021257822A2 (en) * 2020-06-18 2021-12-23 Sparx Therapeutics, Inc. Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (pd-l1)
US20230235047A1 (en) * 2020-06-19 2023-07-27 Innovent Biologics (Suzhou) Co., Ltd. Anti-claudin18.2 antibody and use thereof
CA3196930A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
CN114504642B (zh) * 2020-11-17 2026-03-27 江苏奥赛康生物医药有限公司 一种含抗cldn18.2抗体的液体药物组合物
CN112480248B (zh) * 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
TW202241519A (zh) * 2020-12-23 2022-11-01 捷克商舒迪安生物技術公司 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物
EP4273167A4 (en) * 2020-12-30 2025-03-26 Bio-Thera Solutions, Ltd. ANTI-CLDN18.2 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
CN112940124B (zh) * 2021-04-14 2022-04-05 南京凯地医疗技术有限公司 靶向Claudin18.2的人源化单克隆抗体及其制备方法和应用
CN112979817B (zh) * 2021-04-27 2021-08-13 宝船生物医药科技(上海)有限公司 一种识别抗cldn18_2抗体的单克隆抗体及其制备方法和应用
US12600774B2 (en) * 2021-05-31 2026-04-14 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof
CN116102649A (zh) * 2021-11-11 2023-05-12 上海生物制品研究所有限责任公司 抗cldn18.2单克隆抗体及其应用
WO2023240086A1 (en) * 2022-06-07 2023-12-14 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
TW202415407A (zh) * 2022-06-30 2024-04-16 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗cldn18.2抗體的藥物製劑
CN117777288A (zh) * 2022-09-29 2024-03-29 南京博望医药科技有限公司 抗密蛋白18.2的抗体
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
CN117777306B (zh) * 2023-07-04 2024-08-20 深圳豪石生物科技有限公司 一种靶向cldn18.2的增强型嵌合抗原受体及其用途
CN117777307B (zh) * 2023-09-26 2024-08-20 深圳豪石生物科技有限公司 一种cldn18.2特异性嵌合t细胞受体、嵌合t细胞受体免疫细胞及其应用
TW202541840A (zh) * 2023-12-19 2025-11-01 大陸商蘇州創勝醫藥集團有限公司 包含抗ｃｌａｕｄｉｎ１８．２抗體的製劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
JP5599454B2 (ja) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US8840902B2 (en) 2010-03-16 2014-09-23 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3791896B1 (en) * 2012-05-23 2024-01-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
RS63738B1 (sr) * 2013-02-20 2022-12-30 Astellas Pharma Inc Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HRP20200019T1 (hr) * 2013-03-18 2020-04-03 Astellas Pharma Inc. Terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US10858415B2 (en) * 2014-01-29 2020-12-08 Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh Peptide mimotopes of claudin 18.2 and uses thereof
SI3148579T1 (sl) * 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
WO2016005466A2 (en) * 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
MA40871A (fr) * 2014-10-29 2017-09-05 Novartis Ag Expression directe d'anticorps
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
ES2979068T3 (es) * 2016-07-08 2024-09-24 Crage Medical Co Ltd Anticuerpos para anti-claudina 18A2 y utilización de los mismos

Similar Documents

Publication Publication Date Title
JP2021514664A5 (https=)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2021528047A5 (https=)
JP2021524244A5 (https=)
JP2024531409A5 (https=)
JP2021516057A5 (https=)
JP2020528750A5 (https=)
CN103189392B (zh) ErbB3结合抗体
IL310938A (en) Anti-CCR8 antibodies and their uses
JP2016526904A5 (https=)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2009545325A5 (https=)
JP2017149720A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2022527173A5 (https=)
JP2023546743A5 (https=)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2021517459A5 (https=)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2020522281A5 (https=)
JP2020522280A5 (https=)
JP2022526841A5 (https=)
JP2021512652A5 (https=)
JP2024540148A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用